

Please amend claims 1, 44 and 87 as follows:

sub B1 A1
 1. (amended) A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

B' cont A2
 44. (amended) A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide, and one or more antineoplastic agent, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

B' cont A3
 87. (amended) A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

Please insert the following new claims 107-109:

B1
cont

107. (new) A method for treating or preventing a neoplasia disorder of the lung in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

A4

108. (new) A method for treating or preventing a neoplasia disorder of the lung in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide, and one or more antineoplastic agent, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

109. (new) A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.